Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

NCT05933265 is registered in ClinicalTrials.gov with Lantern Pharma Inc. as lead sponsor.

NCT NCT05933265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05933265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Lantern Pharma Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 9, 2023
Completion date
July 28, 2026
Enrollment
64 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, ddr gene mutation, gbm, metastatic solid tumor, nsclc, pancreatic adenocarcinoma, tnbc - triple-negative breast cancer